HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
A Better Way to Make Money in Today's Market
Learn more now >>
Quote:
Login Free Membership
Search:

 
Analyst Blog  

Baxter: Safe Haven in Troubled Times

July 01, 2009 | Comments: 0
Recommended this article (1)
BAX | EW | BDX | JNJ
Print    Share

Baxter International Inc. (BAX - Analyst Report) recently announced its intention of acquiring the Continuous Renal Replacement Therapy (CRRT) business from Edwards Lifesciences Corp. (EW - Snapshot Report). The deal involves an initial cash payment of roughly $56 million and an additional payment of up to $9 million over the next two years based on achievement of certain milestones revenue. The acquisition is expected to close in Q309 and will have no impact on Baxter’s financial results for fiscal 2009.

CRRT, also known as hemofiltration, is a process of continuous and adjustable removal of excess fluid and waste products resulting from malfunction of the kidney. CRRT duplicates the function of a kidney for 24 hours. Baxter is presently supplying solutions that are used in CRRT treatment globally and is the lone distributor of Edwards’ product in the U.S., Latin America and China.

Baxter is a global medical products and services company with expertise in medical devices, pharmaceuticals and biotechnology. The CRRT acquisition adds a new leaf to the company’s existing renal business. Baxter’s main competitors include names like Becton, Dickinson and Co. (BDX - Analyst Report) and Johnson & Johnson (JNJ - Analyst Report).

Edwards Lifesciences, an Irvine, California-based company, specializes in heart valves and hemodynamic monitoring with particular focus on developing life-saving innovations.

Baxter reported its Q109 results with lower sales primarily due to an unfavorable currency translation. Excluding currency translation, net sales increased 6% year-over-year. Manufacturing efficiencies drove margins higher. We believe that Baxter’s product portfolio will remain relatively insulated from the current economic turmoil and provide investors with handsome returns on a risk-adjusted basis. As such, our recent report has a ‘Buy’ rating for the company’s stock.


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!

More Zacks Resources

Market Summary Nov 07, 2009 15:49 pm ET
DJIA 10023.42  17.46 0.17%
NASD 2112.44  7.12 0.34%
S&P 500 1069.3  2.67 0.25%
Sponsored Links